Melanoma (Clinical Trials)

Phase I Trials Initiated with Three Melanoma Therapeutics

Published in Cancer Weekly, February 10th, 1997

Therion Biologics Corp., Cambridge, Massachusetts, announced that the U.S. National Cancer Institute (NCI) has initiated Phase I clinical trials with three immunotherapeutic vaccines for treating melanoma.

With the initiation of these trials, the company has four related immunotherapeutic vaccines in clinical studies for melanoma, the first of which entered Phase I clinical trials in June 1996. All of the products are based on Therion's recombinant poxvirus vector technology.

The Phase I studies are designed to evaluate the safety and immunogenicity of three potential products - a recombinant vaccinia viral vector encoding the MART-1 melanoma...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-02-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry